Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Renagel
Renagel 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-090093 · Präparat HOS-083991
Digoxin, warfarin, enalapril or metoprolol
In interaction studies in healthy volunteers, Renagel had no effect on the bioavailability of digoxin,
warfarin, enalapril or metoprolol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enalapril (HOS-085479) digoxin (HOS-086172) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-22T13:48:00Z · SHA-256 df52ce5b7ff7e5cee0bb3ecc02e9b51a8d169a413a82f47a77e00432bf9cad77 · Passage 88c03ed92589ac9ff3586d35e2b32e863df05382c9ad6c4282a5abab95680b70 · Zeichen 1621–1801 im Abschnitt
Wechselwirkungen · Renagel
Renagel 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-090108 · Präparat HOS-083991
Digoxin, warfarin, enalapril or metoprolol
In interaction studies in healthy volunteers, Renagel had no effect on the bioavailability of digoxin,
warfarin, enalapril or metoprolol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): enalapril (HOS-085479) digoxin (HOS-086172) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-22T13:48:00Z · SHA-256 df52ce5b7ff7e5cee0bb3ecc02e9b51a8d169a413a82f47a77e00432bf9cad77 · Passage 88c03ed92589ac9ff3586d35e2b32e863df05382c9ad6c4282a5abab95680b70 · Zeichen 1620–1800 im Abschnitt
Wechselwirkungen · DaTSCAN
DaTSCAN 74 MBq/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-090548 · Präparat HOS-084079
Medicines shown during clinical trials not to interfere with DaTSCAN imaging include amantadine,
trihexyphenidyl, budipine, levodopa, metoprolol, primidone, propranolol and selegiline. Dopamine
agonists and antagonists acting on the postsynaptic dopamine receptors are not expected to interfere
with DaTSCAN imaging and can therefore be continued if desired. Medicinal products shown in animal
studies not to interfere with DaTSCAN imaging include pergolide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trihexyphenidyl (HOS-090549) dopamine (HOS-085948) amantadine (HOS-086615) selegiline (HOS-086575) budipine (HOS-090550) propranolol (HOS-084529) levodopa (HOS-086559) metoprolol (HOS-090094) pergolide (HOS-090552) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-25T02:00:00Z · SHA-256 f40f7ad424fba21e279058645a7f9123ad356bfb210f5e9a98e718256e3987ab · Passage 627581950062a07392ac055c73e7e90c92c8cf649c1ecc0bf5d378ea3af20352 · Zeichen 646–1104 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-109361 · Präparat HOS-093187
Effect of parecoxib (or its active metabolite valdecoxib) on the pharmacokinetics of other medicinal
products
Treatment with valdecoxib (40 mg twice daily for 7 days) produced a 3-fold increase in plasma
concentrations of dextromethorphan (CYP2D6 substrate). Therefore, caution should be observed when
coadministering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and
which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) dextromethorphan (HOS-109265) metoprolol (HOS-090094) valdecoxib (HOS-109357)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage b1ca6d2cd1226b59b1df3eb6dadfa83c841417205a1c6ed5f8fd8afe39274b41 · Zeichen 3695–4175 im Abschnitt
Wechselwirkungen · Dynastat
Dynastat 40 mg powder and solvent for solution for injection · Abschnitt 4.5 · PDF-Seite 23
HOS-109408 · Präparat HOS-093187
Effect of parecoxib (or its active metabolite valdecoxib) on the pharmacokinetics of other medicinal
products
Treatment with valdecoxib (40 mg twice daily for 7 days) produced a 3-fold increase in plasma
concentrations of dextromethorphan (CYP2D6 substrate). Therefore, caution should be observed when
coadministering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and
which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) dextromethorphan (HOS-109265) metoprolol (HOS-090094) valdecoxib (HOS-109357)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T17:26:00Z · SHA-256 a94a02bdad229376a395299eccbc2ab09dd742598fb29796b8e5ada490a65e06 · Passage b1ca6d2cd1226b59b1df3eb6dadfa83c841417205a1c6ed5f8fd8afe39274b41 · Zeichen 3696–4176 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-110231 · Präparat HOS-093339
In vitro Glivec inhibits the cytochrome P450 isoenzyme CYP2D6 activity at concentrations similar to
those that affect CYP3A4 activity. Imatinib at 400 mg twice daily had an inhibitory effect on
CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by
approximately 23% (90%CI [1.16-1.30]). Dose adjustments do not seem to be necessary when
imatinib is co-administrated with CYP2D6 substrates, however caution is advised for CYP2D6
substrates with a narrow therapeutic window such as metoprolol. In patients treated with metoprolol
clinical monitoring should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 04ae8bd7c9f92193c74bb5cf1c21fc597411261b0f6c0b8067aa0e3a6ea05873 · Zeichen 2790–3392 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111258 · Präparat HOS-093485
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy
subjects. In study subjects whose blood pressure was not controlled, the reduction was greater
although this reduction was not associated with hypotensive symptoms in the majority of subjects. In
patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a
blood pressure decrease, which (with the exception of alpha blockers -see above-) is, in general, minor
and not likely to be clinically relevant. Analysis of phase 3 clinical trial data showed no difference in
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 1df1359c9bc444a4301229f9fa020c4c04fef72f71cca7d6a70230e986333d2b · Zeichen 3699–5380 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-111303 · Präparat HOS-093485
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy
subjects. In study subjects whose blood pressure was not controlled, the reduction was greater
although this reduction was not associated with hypotensive symptoms in the majority of subjects. In
patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a
blood pressure decrease, which (with the exception of alpha blockers -see above-) is, in general, minor
and not likely to be clinically relevant. Analysis of phase 3 clinical trial data showed no difference in
adverse events in patients taking tadalafil with or without antihypertensive medicinal products.
However, appropriate clinical advice should be given to patients regarding a possible decrease in
blood pressure when they are treated with antihypertensive medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage c0ae8045aff7f8a7fd05a121cf691a3f593453fda4a2a84d3dbb9c19b2f51831 · Zeichen 3702–5657 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-111342 · Präparat HOS-093485
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy
subjects. In study subjects whose blood pressure was not controlled, the reduction was greater
although this reduction was not associated with hypotensive symptoms in the majority of subjects. In
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 9904fece13ee6f6b129a6a22aedb04cd335a2be1fc9883142186e6b2fc89641b · Zeichen 3702–5076 im Abschnitt
Wechselwirkungen · Cholestagel
Cholestagel 625 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-112361 · Präparat HOS-093659
In interaction studies in healthy volunteers, Cholestagel had no effect on the bioavailability of digoxin,
metoprolol, quinidine, valproic acid, and warfarin. Cholestagel decreased the Cmax and AUC of
sustained-release verapamil by approximately 31% and 11%, respectively. Since there is a high degree of
variability in the bioavailability of verapamil, the clinical significance of this finding is unclear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valproic acid (HOS-088515) quinidine (HOS-085593) digoxin (HOS-086172) metoprolol (HOS-090094) warfarin (HOS-085950) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-03T11:58:00Z · SHA-256 d40452a2cad7ddd7eafdc4661259cd69e3d231c506afe3b5edc5d67ea216dce5 · Passage f57bf379ce4978ca3301ac0aee65a98888846bc19f485a7f539cb9b38f36929f · Zeichen 870–1277 im Abschnitt
Wechselwirkungen · Yentreve
YENTREVE 20 mg hard gastro-resistant capsules YENTREVE 40 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-112874 · Präparat HOS-093777
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine
(40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does
not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if YENTREVE is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:33:00Z · SHA-256 d927c7a519b8bbcba3c7ad828fbbce3643ea8a3886fcc0403d91cbec6695f99d · Passage f5263b2aae78af8828902f00ed3e0c2dc4fa81db18866a0b8f1f78e73aa8af66 · Zeichen 2181–2995 im Abschnitt
Wechselwirkungen · Cymbalta
Cymbalta 30 mg hard gastro-resistant capsules Cymbalta 60 mg hard gastro-resistant capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-113277 · Präparat HOS-093901
Medicinal products metabolised by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered at a dose of 60 mg twice daily with a single dose of desipramine, a
CYP2D6 substrate, the AUC of desipramine increased 3-fold. The co-administration of duloxetine (40
mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not
affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is
recommended. Caution is advised if Cymbalta is co-administered with medicinal products that are
predominantly metabolised by CYP2D6 (risperidone, tricyclic antidepressants [TCAs] such as
nortriptyline, amitriptyline, and imipramine) particularly if they have a narrow therapeutic index (such
as flecainide, propafenone and metoprolol).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) propafenone (HOS-084530) tolterodine (HOS-087792) amitriptyline (HOS-085911) desipramine (HOS-086249) flecainide (HOS-086203) imipramine (HOS-085907) risperidone (HOS-086280) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-09T15:40:00Z · SHA-256 a3b2a486f9b4069e76d38032cad9e45c893ee290991d9c0e8b3ea325ef1c101c · Passage 184748d3a5fcda9339ead3f2521f29c9a83708c878d80bf6315817d557c04e72 · Zeichen 2367–3181 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) propafenone (HOS-084530) cisapride (HOS-085610) lovastatin (HOS-086157) flecainide (HOS-086203) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) metoprolol (HOS-090094) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 19–20
HOS-114844 · Präparat HOS-094169
19
H2-receptor antagonists
No interaction study No data are available for An increase in gastric pH that
performed H2-receptor antagonists in may result from H2-receptor
combination with tipranavir and antagonist therapy is not expected
low dose ritonavir. to have an impact on tipranavir
plasma concentrations.
Antiarrhythmics
Amiodarone Based on theoretical The concomitant use of Aptivus,
Bepridil considerations, tipranavir, co- co-administered with low dose
Quinidine administered with low dose ritonavir, with amiodarone,
No interaction study ritonavir, is expected to increase bepridil or quinidine is
performed amiodarone, bepridil and contraindicated due to potential
quinidine concentrations. serious and/or life threatening
events (see section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Flecainide Based on theoretical The concomitant use of Aptivus,
Propafenone considerations, tipranavir, co- co-administered with low dose
Metoprolol (given in heart administered with low dose ritonavir, with flecainide,
failure) ritonavir, is expected to increase propafenone or metoprolol is
No interaction study flecainide, propafenone and contraindicated (see section 4.3)
performed metoprolol concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) ritonavir (HOS-084521) amiodarone (HOS-085596) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 6aa9e00d4b58261863af53d4fabbddef6456a645d8623cbe7ba0ff2c874fe543 · Zeichen 48623–50469 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 10
HOS-116324 · Präparat HOS-094447
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes
CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and
inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the
presence of low dose ritonavir. Co-administration of darunavir and ritonavir with medicinal products
which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result
in increased plasma concentrations of these medicinal products, which could increase or prolong their
therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir with medicinal
products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone)
may result in decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) methadone (HOS-086198) flecainide (HOS-086203) ritonavir (HOS-084521) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 1c69c1e904c5e45f21197cc74aaf3793a744795efd05ba12ed65d139c93b2ca1 · Zeichen 3809–4716 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19–20
HOS-116394 · Präparat HOS-094447
19
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 06bb26e6737c57cc3c74485aceb2076b3feb5ff5bad566ac99081f05e0924029 · Zeichen 52002–57572 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-116503 · Präparat HOS-094447
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes
CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and
inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the
presence of low dose ritonavir. Co-administration of darunavir and ritonavir with medicinal products
which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result
in increased plasma concentrations of these medicinal products, which could increase or prolong their
therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir with medicinal
products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone)
may result in decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) methadone (HOS-086198) flecainide (HOS-086203) ritonavir (HOS-084521) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 1c69c1e904c5e45f21197cc74aaf3793a744795efd05ba12ed65d139c93b2ca1 · Zeichen 1418–2325 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62
HOS-116527 · Präparat HOS-094447
61
Perphenazine Not studied. PREZISTA is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with PREZISTA co-administered
(CYP3A, CYP2D6 and/or P-gp with low dose ritonavir.
inhibition)
Lurasidone Concomitant administration of
Pimozide PREZISTA with low dose
Sertindole ritonavir and lurasidone, pimozide
or sertindole is contraindicated
(see section 4.3).
β-BLOCKERS
Carvedilol Not studied. PREZISTA is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when
Timolol concentrations. co-administering PREZISTA with
(CYP2D6 inhibition) β-blockers. A lower dose of the
β-blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. PREZISTA co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be expected and adverse effects is
Felodipine to increase the plasma concentrations of recommended when these
Nicardipine calcium channel blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with PREZISTA with
Verapamil low dose ritonavir.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of PREZISTA
metabolised by CYP3A ritonavir 100 mg capsules twice daily with low dose ritonavir and
(including were co-administered with 50 g corticosteroids (all routes of
betamethasone, intranasal fluticasone propionate (4 times administration) that are
budesonide, fluticasone, daily) for 7 days in healthy subjects, metabolised by CYP3A may
mometasone, prednisone, fluticasone propionate plasma increase the risk of development of
triamcinolone) concentrations increased significantly, systemic corticosteroid effects,
whereas the intrinsic cortisol levels including Cushing’s syndrome and
decreased by approximately 86% (90% adrenal suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects including metabolised corticosteroids is not
Cushing’s syndrome and adrenal recommended unless the potential
suppression have been reported in benefit to the patient outweighs the
patients receiving ritonavir and inhaled or risk, in which case patients should
intranasally administered fluticasone. The be monitored for systemic
effects of high fluticasone systemic corticosteroid effects.
exposure on ritonavir plasma levels are
unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with PREZISTA
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with PREZISTA
(CYP3A induction) co-administered with low dose
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8b9ea54ec289adeef1a2f9f81165d44d84f0b8d5433cec6f77b7df8c89fd8286 · Zeichen 43290–48378 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 92
HOS-116591 · Präparat HOS-094447
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes
CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and
inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the
presence of low dose ritonavir. Co-administration of darunavir and ritonavir with medicinal products
which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result
in increased plasma concentrations of these medicinal products, which could increase or prolong their
therapeutic effect and adverse reactions. Co-administration of darunavir and ritonavir with medicinal
products primarily metabolised by CYP2C9 (such as warfarin) and CYP2C19 (such as methadone)
may result in decreased systemic exposure to such medicinal products, which could decrease or
shorten their therapeutic effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) methadone (HOS-086198) flecainide (HOS-086203) ritonavir (HOS-084521) metoprolol (HOS-090094) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 1c69c1e904c5e45f21197cc74aaf3793a744795efd05ba12ed65d139c93b2ca1 · Zeichen 3807–4714 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101–102
HOS-116617 · Präparat HOS-094447
101
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) diltiazem (HOS-086288) triamcinolone (HOS-086333) nifedipine (HOS-086289) fluticasone (HOS-108914) nicardipine (HOS-090619) felodipine (HOS-108908) fluticasone propionate (HOS-086331) carvedilol (HOS-115322) risperidone (HOS-086280) amlodipine (HOS-086287) thioridazine (HOS-086281) perphenazine (HOS-116395) calcium (HOS-085615) betamethasone (HOS-090066) dexamethasone (HOS-084535) lead (HOS-085592) budesonide (HOS-086332) pimozide (HOS-085600) mometasone (HOS-114048) ritonavir (HOS-084521) beclomethasone (HOS-086334) lurasidone (HOS-086148) prednisone (HOS-084526) metoprolol (HOS-090094) timolol (HOS-090571) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage ccb6e0bf9fbd4db134b19a5c68f5c32c6656fffa35e00c9b9b966f86c2226743 · Zeichen 51473–57044 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.